Anti-inflammatory and cartilage-protecting effects of an intra-articularly injected anti-TNFα single-chain Fv antibody (ESBA105) designed for local therapeutic use

Annals of the Rheumatic Diseases

Volumn 69, Issue 2, 2010, Pages 443-449

  Urech, D M ^a   Feige, U ^a   Ewert, S ^a   Schlosser, V ^a   Ottiger, M ^a   Polzer, K ^b   Schett, G ^b   Lichtlen, P ^a  

^a ESBATech AG   (Switzerland)

^b UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ESBA 105; INFLIXIMAB; RECOMBINANT TUMOR NECROSIS FACTOR ALPHA; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG PENETRATION; INFLAMMATORY INFILTRATE; JOINT SWELLING; KNEE ARTHRITIS; LEWIS RAT; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; RABBIT; RAT; SYNOVITIS; TIME TO MAXIMUM PLASMA CONCENTRATION;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, MONOCLONAL; APOPTOSIS; ARTHRITIS, EXPERIMENTAL; CARTILAGE, ARTICULAR; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; FIBROBLASTS; INJECTIONS, INTRA-ARTICULAR; MALE; OSTEOARTHRITIS; RABBITS; RATS; RATS, INBRED LEW; RECOMBINANT PROTEINS; SYNOVITIS; TISSUE DISTRIBUTION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 75749138988     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/ard.2008.105775     Document Type: Article

References (57)

1. Sokoloff L. The biology of degenerative joint disease. Perspect Biol Med 1963;7:94-106.
2. Oddis CV. New perspectives on osteoarthritis. Am J Med 1996;100:10-5S.
3. Brandt KD, Radin EL, Dieppe PA, et al. Yet more evidence that osteoarthritis is not a cartilage disease. Ann Rheum Dis 2006;65:1261-4.
4. Hunter DJ, Felson DT. Osteoarthritis. BMJ 2006;332:639-42.
5. Lindblad S, Hedfors E. Arthroscopic and immunohistologic characterization of knee joint synovitis in osteoarthritis. Arthritis Rheum 1987;30:1081-8.
6. Smith MD, Triantafillou S, Parker A, et al. Synovial membrane inflammation and cytokine production in patients with early osteoarthritis. J Rheumatol 1997;24:365-71.
7. Malemud CJ, Islam N, Haqqi TM. Pathophysiological mechanisms in osteoarthritis lead to novel therapeutic strategies. Cells Tissues Organs 2003;174:34-48.
8. Abramson SB. Inflammation in osteoarthritis. J Rheumatol Suppl 2004;70:70-6.
9. Goldring SR, Goldring MB. The role of cytokines in cartilage matrix degeneration in osteoarthritis. Clin Orthop Relat Res 2004;427(Suppl):S27-36.
10. Benito MJ, Veale DJ, FitzGerald O, et al. Synovial tissue inflammation in early and late osteoarthritis. Ann Rheum Dis 2005;64:1263-7.
11. Brennan FM, Chantry D, Jackson AM, et al. Cytokine production in culture by cells isolated from the synovial membrane. J Autoimmun 1989;2(Suppl):177-86.
12. Farahat MN, Yanni G, Poston R, et al. Cytokine expression in synovial membranes of patients with rheumatoid arthritis and osteoarthritis. Ann Rheum Dis 1993;52:870-5.
13. Furuzawa-Carballeda J, Macip-Rodriguez PM, Cabral AR. Osteoarthritis and rheumatoid arthritis pannus have similar qualitative metabolic characteristics and proinflammatory cytokine response. Clin Exp Rheumatol 2008;26:554-60.
14. Amin AR. Regulation of tumor necrosis factor-alpha and tumor necrosis factor converting enzyme in human osteoarthritis. Osteoarthritis Cartilage 1999;7:392-4.
15. Billinghurst RC, Dahlberg L, Ionescu M, et al. Enhanced cleavage of type II collagen by collagenases in osteoarthritic articular cartilage. J Clin Invest 1997;99:1534-45.
16. Squires GR, Okouneff S, Ionescu M, et al. The pathobiology of focal lesion development in aging human articular cartilage and molecular matrix changes characteristic of osteoarthritis. Arthritis Rheum 2003;48:1261-70.
17. Dingle JT, Page Thomas DP, Hazleman B. The role of cytokines in arthritic diseases: in vitro and in vivo measurements of cartilage degradation. Int J Tissue React 1987;9:349-54.
18. Pettipher ER, Higgs GA, Henderson B. Interleukin 1 induces leukocyte infiltration and cartilage proteoglycan degradation in the synovial joint. Proc Natl Acad Sci 1986;83:8749-53.
19. Pettipher ER, Higgs GA, Henderson B. Arthritogenic activity of interleukin 1. Agents Actions 1986;19:337-8.
20. Borella L, Eng CP, DiJoseph J, et al. Rapid induction of early osteoarthritic-like lesions in the rabbit knee by continuous intra-articular infusion of mammalian collagenase or interleukin-1. Agents Actions 1991;34:220-2.
21. van de Loo FA, Joosten LA, van Lent PL, et al. Role of interleukin-1, tumor necrosis factor alpha, and interleukin-6 in cartilage proteoglycan metabolism and destruction. Effect of in situ blocking in murine antigen- and zymosan-induced arthritis. Arthritis Rheum 1995;38:164-72.
22. Bolon B, Campagnuolo G, Zhu L, et al. Interleukin-1beta and tumor necrosis factor-alpha produce distinct, time-dependent patterns of acute arthritis in the rat knee. Vet Pathol 2004;41:235-43.
23. Feige U, Karbowski A, Rordorf-Adam C, et al. Arthritis induced by continuous infusion of hr-interleukin-1 alpha into the rabbit knee-joint. Int J Tissue React 1989;11:225-38.
24. Kobayashi M, Squires GR, Mousa A, et al. Role of interleukin-1 and tumor necrosis factor alpha in matrix degradation of human osteoarthritic cartilage. Arthrit Rheum 2005;52:128-35.
25. Wieland HA, Michaelis M, Kirschbaum BJ, et al. Osteoarthritis: an untreatable disease? Nat Rev Drug Discov 2005;4:331-44.
26. Abramson SB, Yazici Y. Biologics in development for rheumatoid arthritis: relevance for osteoarthritis. Adv Drug Deliv Rev 2006;58:212-25.
27. Jüni P, Reichenbach S, Trelle S, et al. Efficacy and safety of intraarticular hylan or hyaluronic acids for osteoarthritis of the knee: a randomized controlled trial. Arthritis Rheum 2007;56:3610- 9.
28. Onel E, Kolsun K, Kauffman JI. Post-hoc analysis of a head-to-head hyaluronic acid comparison in knee osteoarthritis using the 2004 OMERACT-OARSI responder criteria. Clin Drug Invest 2008;28:37-45.
29. Waddell DD. Viscosupplementation with hyaluronans for osteoarthritis of the knee: clinical efficacy and economic implications. Drugs Aging 2007;24:629-42.
30. Pyne D, Ioannou Y, Mootoo R, et al. Intra-articular steroids in knee osteoarthritis: a comparative study of triamcinolone hexacetonide and methylprednisolone acetate. Clin Rheumatol 2004;23:116-20.
31. Smith MD, Wetherall M, Darby T, et al. A randomized placebo-controlled trial of arthroscopic lavage versus lavage plus intra-articular corticosteroids in the management of symptomatic osteoarthritis of the knee. Rheumatology 2003;42:1477-85.
32. Raynauld JP, Buckland-Wright C, Ward R, et al. Safety and efficacy of long-term intraarticular steroid injections in osteoarthritis of the knee: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2003;48:370-7.
33. Goldring MB. Anticytokine therapy for osteoarthritis. Expert Opin Biol Ther 2001;1:817-29.
34. Chevalier X, Giraudeau B, Conrozier T, et al. Safety study of intraarticular injection of interleukin 1 receptor antagonist in patients with painful knee osteoarthritis: a multicenter study. J Rheumatol 2005;32:1317-23.
35. Grunke M, Schulze-Koops H. Successful treatment of inflammatory knee osteoarthritis with tumour necrosis factor blockade. Ann Rheum Dis 2006;65:555-6.
36. Magnano MD, Chakravarty EF, Broudy C, et al. A pilot study of tumor necrosis factor inhibition in erosive/inflammatory osteoarthritis of the hands. J Rheumatol 2007;34:1323-7.
37. Hudson PJ, Souriau C. Engineered antibodies. Nat Med 2003;9:129-34.
38. Yokota T, Milenic DE, Whitlow M, et al. Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms. Cancer Res 1992;52:3402-8.
39. Larson SM, EI-Shirbiny AM, Divgi CR, et al. Single chain antigen binding protein (sFv CC49): first human studies in colorectal carcinoma metastatic to liver. Cancer 1997;80(Suppl):2458-68.
40. Batra SK, Jain M, Wittel UA, et al. Pharmacokinetics and biodistribution of genetically engineered antibodies. Curr Opin Biotechnol 2002;13:603-8.
41. Graff CP, Wittrup KD. Theoretical analysis of antibody targeting of tumor spheroids: Importance of dosage for penetration, and affinity for retention. Cancer Res 2003;63:1288-96.
42. Ottiger M, Thiel MA, Feige U, et al. Efficient intraocular penetration of topical anti-TNF-α single-chain antibody (ESBA105) to anterior and posterior segment without penetration enhancer. Invest Ophthalmol Vis Sci 2009;50:779-86.
43. Furrer E, Berdugo M, Stella C, et al. Pharmacokinetics and posterior segment biodistribution of ESBA105, an anti-TNF-α single-chain antibody, upon topical administration to the rabbit eye. Invest Ophthalmol Vis Sci 2009;50:771-8.
44. Scallon B, Cai A, Solowski N, Rosenberg A, et al. Binding and functional comparisons of two types of tumor necrosis factor antagonists. J Pharmacol Exp Ther 2002;301:418-26.
45. Fitch JC, Rollins S, Matis L, et al. Pharmacology and biological efficacy of recombinant, humanized, single-chain antibody C5 complement inhibitor in patients undergoing coronary artery bypass graft surgery with cardiopulmonary bypass. Circulation 1999;100:2499-506.
46. Schäfers M, Sorkin LS, Sommer C. Intramuscular injection of tumor necrosis factor-alpha induces muscle hyperalgesia in rats. Pain 2003;104:579-88.
47. Sachs D, Queiroz Cunha F, Poole S, et al. Tumour necrosis factor-α, interleukin-1β and interleukin-8 induce persistent mechanical nociceptor hypersensitivity. Pain 2002;96:89-97.
48. Schottelius AJ, Moldawer LL, Dinarello CA, et al. Biology of tumor necrosis factor-alpha: implications for psoriasis. Exp Dermatol 2004;13:193-222.
49. Hill CL, Hunter DJ, Niu J, et al. Synovitis detected on magnetic resonance imaging and its relation to pain and cartilage loss in knee osteoarthritis. Ann Rheum Dis 2007;66:1599-603.
50. Elliott MJ, Maini RN, Feldmann M, et al. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet 1994;344:1105-10.
51. Shergy WJ, Isern RA, Cooley DA, et al. Profiling remicade onset with MTX in a prospective trial. Open label study to assess infliximab safety and timing of onset of clinical benefit among patients with rheumatoid arthritis. J Rheumatol 2002;29:667-77.
52. Alstergren P, Kopp S. Insufficient endogenous control of tumor necrosis factor-alpha contributes to temporomandibular joint pain and tissue destruction in rheumatoid arthritis. J Rheumatol 2006;33:1734-9.
53. Feldmann M, Maini SR. Role of cytokines in rheumatoid arthritis: an education in pathophysiology and therapeutics. Immunol Rev 2008;223:7-19.
54. Maroudas A. Transport of solutes through cartilage: permeability to large molecules. J Anat 1976;122(Pt 2):335-47.
55. van Lent PL, van den Berg WB, Schalkwijk J, et al. The impact of protein size and charge on its retention in articular cartilage. J Rheumatol 1987;14:798-805.
56. van Lent PL, van den Bersselaar L, Grutters GJ, et al. Fate of antigen after intravenous and intraarticular injection into mice. Role of molecular weight and charge. J Rheumatol 1989;16:1295-303.
57. Nestorov I. Clinical pharmacokinetics of TNF antagonists: how do they differ? Semin Arthritis Rheum 2005;34(5 Suppl 1):12-8.